Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. Journal of the National Comprehensive Cancer Network : JNCCN Greenberg, P. L., Stone, R. M., Abaza, Y., Al-Kali, A., Anand, S., Ball, B., Bennett, J. M., Borate, U., Brunner, A. M., Chai-Ho, W., Curtin, P., DeZern, A. E., Gaensler, K., Gahvari, Z., Garcia-Manero, G., Griffiths, E. A., Haque, T., Jacoby, M., Jonas, B. A., Keel, S., Khanal, R., Kishtagari, A., Madanat, Y., Maness, L. J., McCurdy, S. R., McMahon, C., Odenike, O., Osman, A., Reddy, V. V., Sallman, D. A., Sayar, H., Shallis, R., Singh, A., Tanaka, T., Thota, S., Kovach, E., Nguyen, J., Hochstetler, C. 2025; 23 (3): 66-75

Abstract

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.

View details for DOI 10.6004/jnccn.2025.0013

View details for PubMedID 40073835